A new approach to weight loss research is challenging one of the biggest assumptions behind popular weight loss drugs: Are ...
This week the U.S. Food and Drug Administration approved a second GLP-1 pill for weight loss. The drug, called Foundayo, resulted in an average of 27 pounds lost in 72 weeks ...
The latest experimental GLP-1 from Eli Lilly isn’t just a diabetes drug — it also facilitates weight loss. Known as “triple-G,” injectable retatrutide levies a triple whammy on the GLP-1, GIP and ...
A new Cleveland Clinic study of nearly 8,000 patients found that people who stop popular GLP-1 weight-loss drugs often avoid major weight regain in real-world settings. Researchers say many patients ...
But while Ozempic is arguably the most recognizable drug in its class, it isn’t the only medication approved for weight management. Others include Wegovy and Saxenda, while newer drugs like ...
Eli Lilly CEO David Ricks discusses the challenges of scaling production for weight-loss drugs, with the expectation that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results